The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Company to launch product after the expiry of semaglutide patent in India
Subscribe To Our Newsletter & Stay Updated
